The main objective of this study is to evaluate outcomes of bladder preservation treatment for patients with muscle-invasive bladder cancer.
Methods and Study Design
38 patients with histologically proven muscle-invasive bladder cancer treated at our department between January 2008 and December 2013 were analyzed retrospectively. Age, gender, pathology, stage, 3-year overall survival, 3-year disease-free survival, radiotherapy (RT) dose, genitourinary and gastrointestinal toxicity scores and response evaluation of the patients were recorded. 3-year overall survival and 3-year disease-free survivals were calculated by Kaplan-Meier method along with the analysis of gender, pathology, stage and therapy response of the study group.
Results
33 patients (86.8%) were managed with concomitant chemoradiotherapy whereas 5 patients (13.2%) received only radiation therapy due to renal insufficency and comorbid diseases. 6 (15.8%) out of 38 patients had partial response (PR) and remaining 32 (84.2%) patients experienced complete response (CR). The PR group underwent salvage cystectomy and CR group had been followed-up after radical radiotherapy. Mean age of the group was 70.9 (range 45–90) years. 26 of all patients were male (68.4%) and 12 were female (31.6%). Mean follow-up time after completion of radiotherapy was 24.7 months (range 12–40). Mean RT dose was 64 Gy (range 60–66). 3-year overall survival was 64% and 3-year disease free survival was 73%.
Conclusions
Bladder preserving approach is an alternative definitive therapy solution to radical cystectomy in the treatment of muscle-invasive bladder cancer with less morbidity, preserved natural bladder, and high quality of life.
KhaderJ.FarahN.SalemA.Bladder preservation by concurrent chemoradiation for muscle-invasive bladder cancer: applicability in low-income countries. Reports of Practical Oncology and Radiotherapy.2011; 16: 178–183.
2.
PelucchiC.BosettiC.NegriE.MalvezziM.La VecchiaC.Mechanisms of disease: the epidemiology of bladder cancer. Nat Clin Pract Urol.2006; 3(6): 327–340.
3.
AluwiniS.van RooijP.H.KirkelsW.J.BoormansJ.L.Kolkman-DeurlooI.K.WijnmaalenA.Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surgery in bladder cancer patients: long-term results [corrected]. Int J Radiat Oncol Biol Phys.2014; 88(3): 611–617.
4.
SteinJ.P.LieskovskyG.CoteR.Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol.2001; 19(3): 666–675.
5.
ShelleyM.D.WiltT.J.BarberJ.MasonM.D.A meta-analysis of randomised trials suggests a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: are these data relevant to modern practice?Clin Oncol (R Coll Radiol).2004; 16(3): 166–171.
6.
RodelC.WeissC.SauerR.Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol.2006; 24(35): 5536–5544.
7.
KotwalS.ChoudhuryA.JohnstonC.PaulA.B.WhelanP.KiltieA.E.Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys.2008; 70(2): 456–463.
8.
KonetyB.R.JoslynS.A.Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol.2003; 170(5): 1765–1771.
9.
MunroN.P.SundaramS.K.WestonP.M.A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. Int J Radiat Oncol Biol Phys.2010; 77(1): 119–124.
EdgeS.B.ByrdD.R.ComptonC.C.; American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual. 7th ed. Berlin: Springer2009.
12.
AnacakY.YalmanD.OzsaranZ.HaydaroğluA.Late radiation effects to the rectum and bladder in gynecologic cancer patients: the comparison of LENT/SOMA and RTOG/EORTC late-effects scoring systems. Int J Radiat Oncol Biol Phys.2001; 50(5): 1107–1112.
13.
HayterC.R.PaszatL.F.GroomeP.A.SchulzeK.MackillopW.J.The management and outcome of bladder carcinoma in Ontario, 1982–1994. Cancer.2000; 89(1): 142–151.
14.
PloussardG.DaneshmandS.EfstathiouJ.A.Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol.2014; 66(1): 120–137.
15.
MichaelsonM.D.ShipleyW.U.HeneyN.M.ZietmanA.L.KaufmanD.S.Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder. Br J Cancer.2004; 90(3): 578–581.
16.
ZietmanA.L.SaccoD.SkowronskiU.Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol.2003; 170(5): 1772–1776.
17.
HaganM.P.WinterK.A.KaufmanD.S.RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys.2003; 57(3): 665–672.
18.
LeeC.Y.YangK.L.KoH.L.Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival. Radiat Oncol.2014; 9(1): 213.
19.
CoppinC.M.GospodarowiczM.K.JamesK.; The National Cancer Institute of Canada Clinical Trials Group. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol.1996; 14(11): 2901–2907.
20.
TurgeonG.A.SouhamiL.CuryF.L.Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. Int J Radiat Oncol Biol Phys.2014; 88(2): 326–331.
21.
ZygogianniA.KoulouliasV.ArmpiliaC.A weekly hypofractionated radiotherapeutic schedule for bladder carcinoma in elderly patients: local response, acute and late toxicity, dosimetric parameters and pain relief. J BUON.2013; 18(2): 407–412.
22.
JamesN.D.HussainS.A.HallE.; BC2001 Investigators. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med.2012; 366(16): 1477–1488.
23.
HenningsohnL.WijkströmH.DickmanP.W.BergmarkK.SteineckG.Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol.2002; 62(2): 215–225.
24.
HorwichA.DearnaleyD.HuddartR.A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol.2005; 75(1): 34–43.
25.
Rincón MayansA.Rosell CostaD.Zudaire BergeraJ.J.[Response and progression-free survival in T2 to T4 bladder tumors treated with trimodality therapy with bladder preservation] [article in Spanish]. Actas Urol Esp.2010; 34(9): 775–780.
26.
LangsenlehnerT.DöllerC.QuehenbergerF.Treatment results of radiation therapy for muscle-invasive bladder cancer. Strahlenther Onkol.2010; 186(4): 203–209.
27.
WittlingerM.RodelC.M.WeissC.Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol.2009; 93(2): 358–363.
28.
TunioM.A.HashmiA.QayyumA.MohsinR.ZaeemA.Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys.2012; 82(3): e457–e462.
29.
HuddartR.A.HallE.HussainS.A.Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys.2013; 87(2): 261–269.
30.
TesterW.PorterA.AsbellS.Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85–12. Int J Radiat Oncol Biol Phys.1993; 25(5): 783–790.
31.
EfstathiouJ.A.BaeK.ShipleyW.U.Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol.2009; 27(25): 4055–4061.
